Compared side by side
Teriparatide vs abaloparatide: how they differ
The short answer
Both are daily bone-building shots that act on the same receptor, PTH1: teriparatide is a copy of the first 34 amino acids of human parathyroid hormone, and abaloparatide a 34-amino-acid peptide modelled on a related hormone, PTHrP. Both are FDA-approved for osteoporosis at high risk of fracture, teriparatide as Forteo since 2002 and abaloparatide as Tymlos since 2017, for up to 2 years in most people. In their main trials, teriparatide cut new spine fractures by 65%, and on abaloparatide they fell from 4.2% on placebo to 0.6% over 18 months.
Side by side
| Compared | Teriparatide | Abaloparatide |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Forteo, Bonsity, PTH 1-34, rhPTH(1-34), LY333334 | Tymlos, BA058 |
| What it is | A daily shot of the active part of parathyroid hormone (Forteo) that builds new bone, rather than only slowing bone loss as most osteoporosis drugs do. | A daily shot (Tymlos) that builds new bone, a close relative of teriparatide modelled on a different natural hormone, PTHrP. |
| How it works | A bone-building copy of the first 34 amino acids of human parathyroid hormone (PTH), the active part of the 84-amino-acid hormone that controls calcium in bone and kidney. The pattern of exposure decides what it does: a short daily pulse stimulates the cells that build bone (osteoblasts) more than those that remove it, so new bone forms on the inner and outer surfaces, while a constant excess of PTH, as in an overactive parathyroid, breaks bone down. FDA-approved in 2002 (Forteo) for osteoporosis at high fracture risk in postmenopausal women, in men, and with long-term steroid use. | A bone-building 34-amino-acid peptide modelled on PTHrP, the parathyroid-hormone-related peptide (76% the same as its active part, 41% the same as teriparatide's PTH). It activates the PTH1 receptor on bone cells, and a daily dose stimulates the bone-building cells, so new bone forms on the inner and outer surfaces. FDA-approved in 2017 for postmenopausal women with osteoporosis at high fracture risk, and later for men; it is the sibling of teriparatide, with one dose and the same 2-year limit. |
| Commonly reported | Little day to day, sometimes joint pain, nausea, leg cramps or light-headedness after the first shots. FDA-approved since 2002, for up to 2 years in most people; some people also read about it for fracture healing, which the label does not cover. | Redness where the shot goes in, and dizziness or a fast heartbeat for a while after the first doses. FDA-approved since 2017, for up to 2 years. |
| Studied range | FDA label: 20 mcg, starting dose 20 mcg. | FDA label: 80 mcg, starting dose 80 mcg. |
| How often | Daily SubQ | Daily SubQ |
| Half-life | ~1 hour (FDA label) | ~1 hour (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | The label limits use to 2 years in a lifetime unless fracture risk stays or returns high. Its fracture trial ran a median of 19 months in women; the men's trial a median of 10 to 11 months. | The label does not recommend more than 2 years in a lifetime; its fracture trial ran 18 months, followed in the trial by alendronate, which kept the lower fracture risk through 24 more months. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Joint pain, pain, nausea, dizziness, leg cramps, light-headedness on standing (first doses), brief rise in blood calcium | Injection site redness, dizziness, nausea, headache, palpitations, fatigue, high urine calcium |
- Category
- TeriparatideHealing & recovery
- AbaloparatideHealing & recovery
- Also known as
- TeriparatideForteo, Bonsity, PTH 1-34, rhPTH(1-34), LY333334
- AbaloparatideTymlos, BA058
- What it is
- TeriparatideA daily shot of the active part of parathyroid hormone (Forteo) that builds new bone, rather than only slowing bone loss as most osteoporosis drugs do.
- AbaloparatideA daily shot (Tymlos) that builds new bone, a close relative of teriparatide modelled on a different natural hormone, PTHrP.
- How it works
- TeriparatideA bone-building copy of the first 34 amino acids of human parathyroid hormone (PTH), the active part of the 84-amino-acid hormone that controls calcium in bone and kidney. The pattern of exposure decides what it does: a short daily pulse stimulates the cells that build bone (osteoblasts) more than those that remove it, so new bone forms on the inner and outer surfaces, while a constant excess of PTH, as in an overactive parathyroid, breaks bone down. FDA-approved in 2002 (Forteo) for osteoporosis at high fracture risk in postmenopausal women, in men, and with long-term steroid use.
- AbaloparatideA bone-building 34-amino-acid peptide modelled on PTHrP, the parathyroid-hormone-related peptide (76% the same as its active part, 41% the same as teriparatide's PTH). It activates the PTH1 receptor on bone cells, and a daily dose stimulates the bone-building cells, so new bone forms on the inner and outer surfaces. FDA-approved in 2017 for postmenopausal women with osteoporosis at high fracture risk, and later for men; it is the sibling of teriparatide, with one dose and the same 2-year limit.
- Commonly reported
- TeriparatideLittle day to day, sometimes joint pain, nausea, leg cramps or light-headedness after the first shots. FDA-approved since 2002, for up to 2 years in most people; some people also read about it for fracture healing, which the label does not cover.
- AbaloparatideRedness where the shot goes in, and dizziness or a fast heartbeat for a while after the first doses. FDA-approved since 2017, for up to 2 years.
- Studied range
- TeriparatideFDA label: 20 mcg, starting dose 20 mcg.
- AbaloparatideFDA label: 80 mcg, starting dose 80 mcg.
- How often
- TeriparatideDaily SubQ
- AbaloparatideDaily SubQ
- Half-life
- Teriparatide~1 hour (FDA label)
- Abaloparatide~1 hour (FDA label)
- Route
- TeriparatideSubQ injection
- AbaloparatideSubQ injection
- Typical run
- TeriparatideThe label limits use to 2 years in a lifetime unless fracture risk stays or returns high. Its fracture trial ran a median of 19 months in women; the men's trial a median of 10 to 11 months.
- AbaloparatideThe label does not recommend more than 2 years in a lifetime; its fracture trial ran 18 months, followed in the trial by alendronate, which kept the lower fracture risk through 24 more months.
- Evidence
- TeriparatideEstablished: clinical trials or FDA-approved use exists
- AbaloparatideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- TeriparatideJoint pain, pain, nausea, dizziness, leg cramps, light-headedness on standing (first doses), brief rise in blood calcium
- AbaloparatideInjection site redness, dizziness, nausea, headache, palpitations, fatigue, high urine calcium
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Teriparatide
- Day 1–14 · 20 mcg The first shots, sitting down
- Day 14–90 A short calcium pulse each day
- Day 90–365 New bone, built in the background
- Day 365–730 Fewer fractures, and the 2-year line
Abaloparatide
- Day 1–14 · 80 mcg The first shots, sitting down
- Day 14–60 Redness where the shot goes in
- Day 60–365 New bone, built in the background
- Day 365–730 Fewer fractures, then the 2-year line
Questions people ask
How long do teriparatide and abaloparatide last?
The half-life of teriparatide is ~1 hour (FDA label). The half-life of abaloparatide is ~1 hour (FDA label).
How often are teriparatide and abaloparatide taken?
Teriparatide: daily SubQ. Route: SubQ injection. Abaloparatide: daily SubQ. Route: SubQ injection.
How are teriparatide and abaloparatide dosed in research?
The FDA label range for teriparatide is 20 mcg, with a 20 mcg starting dose. The FDA label range for abaloparatide is 80 mcg, with a 80 mcg starting dose.
What are the common side effects of teriparatide and abaloparatide?
For teriparatide, the library lists: joint pain, pain, nausea, dizziness, leg cramps, light-headedness on standing (first doses), brief rise in blood calcium. For abaloparatide: injection site redness, dizziness, nausea, headache, palpitations, fatigue, high urine calcium.